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ABSTRACT 
The study compares the efficacy of risperidone and haloperidol in patients of schizophrenia 
on various clinical and psychosocial parameters. 
In the present open, comparative study, in patients suffering from schizophrenia (DSM-IV), 
50 patients each were randomly treated with risperidone and haloperidol over a period of 1 year. 
The clinical improvement was judged on PANSS (Positive and Negative Symptom Scale) and CGIS 
(Clinical Global Impression Scale). The improvement in psychosocial functioning and other areas 
was judged using a five point scale (0-4). Though the improvement on PANSS was comparable in 
both the groups except on the general psychopathology subscale, on CGIS a better improvement 
profile was observed in risperidone group. In the other psychosocial areas such as social functioning, 
productivity and education a significantly more number of patients showed improvement in risperidone 
group as compared to haloperidol group. In significantly less number of patients suicidality and 
^hospitalization was found in risperidone group as compared to haloperidol group. 
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In the last decade number of double blind 
trials have compared risperidone with haloperidol 
(Claus et al ,1992; Chouinard et al.,1993; 
Ceskova & Svestka,1993; Marder & Meibach, 
1994, Peuskens.1995), These studies have 
established its efficacy in positive as well as 
negative symptoms of schizophrenia and its 
safety in terms of low incidence of 
extrapyramidal reactions as compared to 
haloperidol. From these studies, it seems that, 
typical antipsychotics like haloperidol are not 
very effective against negative symptoms of 
schizophrenia. While the atypical antipsychotics 
like risperidone are useful in alleviating negative 
symptoms of schizophrenia. Therefore, 
risperidone may be more effective in improving 
the overall quality of life. 
Over the last decade more and more 
attention is being paid to the concept of health 
related quality of life' especially in patients 
suffering from chronic disorders like 
schizophrenia. This concept attempts to consider 
the patients holistically (Bech,1993; Bech & 
Angst, 1996) Lehman has discussed this issue at 
length and has also developed an instrument 
'quality of life interview' for patients of 
schizophrenia (Lehman et al.,1983; Lehman, 
1996). When interpreting quality of life information 
in the context of intervention in schizophrenia 
Lehman has emphasized that one needs to study 
the various changes in patient's environment like 
housing, financial independence, productivity etc. 
There seems to be a mutual relationship 
between pharmacotherapy and improvement in 
quality of life The pharmacotherapy, by 
improving signs and symptoms, improves the 
quality of life and this in turn improves the 
compliance of the patients. 
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Research data indicate that newer 
antipsychotic drug like risperidone, with 
significant antagonist activity at the 5HT end D2 
receptors may be more effective than currently 
available dopamine antagonists at treating 
positive as well as negative symptoms of 
schizophrenia (Carmen etal., 1995). The concept 
of health related quality of life emphasizes that 
apart from alleviation in signs and symptoms, 
the concept of improvement should also take 
into consideration the effect of clinical recovery 
into the other areas of life. Thus, the present 
study was undertaken to examine the 
comparative efficacy of risperidone and 
haloperidol in improvement in the signs and 
symptoms as well as improvement in the other 
areas of life which are important for social 
integration and overall improvement in quality 
of life in patients suffering from schizophrenia. 
MATERIAL AND METHOD 
Patients' selection : 125 consecutive patients 
suffering from schizophrenia (DSM-IV) and 
admitted in the hospital for acute exacerbation 
of schizophrenia were selected for the study, after 
taking a due informed consent from them and 
their relatives, over a period of 1 year. During 
the acute stage all of them were treated with 
haloperidol in the dose range of 15-30 mg/day 
(mean (SD)=23.8 (4.6) mg/day) over a period of 
2 to 4 weeks. After the satisfactory clinical control 
of acute symptoms the patients were randomly 
divided into two groups (satisfactory control was 
judged clinically based on improvement in acute 
signs and symptoms, by a senior psychiatrist). 
Group-1 patients were gradually switched over 
to risperidone 2 mg/day over a period of 2 weeks 
while group-2 patients were continued on the 
maintenance dose of haloperidol which ranged 
from 5-15 mg/day (mean (SD)=9 2 (3.8) mg/day). 
Each of these patients were then followed up for 
a period of 12 months. During the follow up 
period 12 patients were lost to follow up and 13 
patients had to be switched over to other 
medications Thus, at the end both the groups 
had 50 patients each. 
Medication . As mentioned earlier all the patients 
in group-1 were switched to risperidone at the 
dose of 2 mg/day while all the patients in group-
2 were continued on haloperidol. The dose 
schedule in both the groups was flexible and it 
was titrated according to the clinical discretion 
of the study team. Concomitant antiparkinsonian 
agent were administered as and when required. 
Evaluation : In order to have an uniform clinical 
assessment of improvement or exacerbation, 
patients were rated on Clinical Global 
Improvement Scale (CGIS) at the baseline and 
at the end of the study. 
They were also assessed on Positive and 
Negative Symptoms Scale (PANSS) (Kay et 
al., 1987,1988) at the beginning of the study and 
at the end of the study. 
The improvement in psychosocial aspect 
was assessed on a five point scale (0-4) using 
operational criteria in the following areas : 
i) social functioning; ii) productivity; iii) economic 
independence; iv) education; v) suicidality; 
vi) ^hospitalization and vii) exacerbation of 
symptoms. 
This scale was designed for the present 
study by the authors themselves. 
RESULTS 
In Group-1, there were 29 males and 21 
females. The mean (so) age was 36.2 (3.5) and 
mean (SD) duration of illness was 5.6 (3.8) years. 
While in Group-2, there were 30 males and 20 
female. The mean (SD) age was 31 8 (4 8) and 
mean (SD) duration of illness was 5
 1 (3 2) years 
Both the groups were comparable on duration of 
illness and male to female ratio. Though there 
was a significant difference in the mean age of 
the two groups (1-° 7i. d.f.=48, p<0.05), this 
difference was more oiatistical rather than clinical. 
As evident from table-1, there was a 
significant reduction in total mean score and all 
the subscales scores of PANSS at the end of 
the study period There was no significant 
difference between the two groups as far as the 
improvement assessed by PANSS was 
concerned in all but one subscale. A significantly 
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TABLE 1 
CHANGE IN PANSS SCORES 
Sub-Scales 
Positive 
Negative 
Gen-Psy 
Total 
PANSS SCORE - MEAN (SD) 
RISPERIDONE GROUP 
Baseline 
20.2 
(4 2) 
31.1 
(4.2) 
40.4 
(5.6) 
91.9 
(5 9) 
At the end 
ofl 
© 
@ 
@ 
@ 
year 
09.0 
(33) 
128 
(3.6) 
20.0 
(3.6)* 
41.5 
(3.6) 
Reduction 
mean (sd) 
(% reduction) 
11.2(4.2) 
(555%) 
18.3(4.0) 
(58.8%) 
20.4(4.9) 
(50.5%) 
50.4(5.7) 
(54.8%) 
HALOPERIDOL GROUP 
Baseline 
21 0 
(3.2) . 
29.3 
(3.4) 
39.5 
(4.4) 
89.1 
(4.8) 
At the end 
of 1 
@ 
@ 
@ 
@ 
year 
11.0 
(3.1) 
14.3 
(3.3) 
12.5 
(2.2)* 
37.1 
(34) 
Reduction 
mean (sd) 
(% reduction) 
10.0(3.0) 
(47.6%) 
15.0(3.5) 
(51.2%) 
27.0(3.7) I 
(68.4%) 
52.0(4.1) 
(58.4%) 
@ Baseline scores and scores at the end of 1 year were compared in both the groups using unpaired t-test. 
@ A significant difference was noticed on all the subscale scores and total scores in baseline scores and scores 
at the end of 1 year in both the groups. 
The baseline scores between the groups and scores at the end of 1 year between the groups were compared 
using unpaired t-test 
Significant difference was noticed between the two groups in the scores at the end of 1 year in general 
psychopathology sub-scale (t=2.15. d f =<8, p<0.05). 
No other differences were found to be significant between the groups. 
more reduction (68.4%) was observed in general 
psychopathology subscale in haloperidol group 
as compared to risperidone group (50.5%). 
TABLE 2 
CLINICAL IMPROVEMENT AT THE 
END OF 1 YEAR (CGIS) 
Risperidone group  Haloperidol group 
Very much 
Much 
Minimal 
18 
22 
10 
05 
36 
09 
X =10 77 p< 01 
On CGIS. a significantly more number of 
patients showed very much improvement in 
risperidone group as compared to haloperidol group. 
Table-3 shows the improvement in different 
psychosocial factors. As there were only 50 
patients in each group, in 5 by 2 table, observed 
and expected values in many cells were less than 
5 Therefore the tables were dichotomized for the 
purpose of analysis Patients having scores of 0 
and 1 were considered together in one group and 
patients having scores 2, 3, and 4. were 
considered together 
A significantly more number of patients 
from Group-1 showed improvement in the areas 
of social functioning, productivity, education. 
Similarly, significantly less number of patients 
in Group-1 had suicidal ideation or attempts and 
rehospitalization. No significant difference was 
observed between the two groups on the 
parameters of economic independence and 
exacerbation. 
DISCUSSION 
As mentioned earlier, number of studies 
have compared the efficacy of risperidone with 
haloperidol in patients of schizophrenia (Claus 
et al.,1992; Chouinard et al.,1993; Ceskova & 
Svestka.1933; Marder & Meibach.1994; 
Peuskens. 1995). These studies have established 
the efficacy of risperidone on positive as well as 
negative symptoms of schizophrenia and its 
safety in term of low incidence of extrapyramidal 
reactions. 
In the present study,.there was no 
significant difference noticed between the 
risperidone and haloperidol group on PANSS 
except on general psychopathology subscale. A 
significantly more reduction was observed in 
haloperidol group on general psychopathology 
subscale. In contrast, a signifiantly more number 
of patients were rated as very much improved' 
on CGIS in risperidone group as compare to 
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TABLE 3 
CLINICAL IMPROVEMENT IN PSYCHOSOCIAL 
AREAS AT THE END OF 1 YEAR (CGIS) 
Risperidone Haloperidol 
group group 
a) Social functioning 
0 Withdrawn & 
limited interaction ^ 16 28 
1 Express desire of interaction • 
2 Definite evidence of 
improved functioning 
3 Improvement functioning 
and relationship | 34 22 
4. Functioning with satisfaction • 
X
2 = 4.91,p<0.02 
b) Productivity 
0. Unproductive 1 15 32 
1 Expression of productivity 
2. Occasional productive 
3 Productive with support ' ^-35 18 
4, Productive without support 
X
2= 10.28, p<0.001 
c) Economic independence 
0. Complete dependence \ 19 21 
1. Desire to earn 
2. Attempt with failure 
3. Attempt with success >31 29 
4. Satisfactorily independent 
X
J = 0 04, N.S. 
d) Education 
0 Unable to resume ~) 10 15 
1 Feels confidence but 
unable to start 
2. Attempt but not sustained "J 
3. Sustained without satisfaction > 40 25 
4. Sustained with satisfaction * 
X- = 8 61,p<0.003 
e) Suiadality 
0. No intent. \ 45 33 
1. Occasional death wish 
2 Contemplating suicide 
3. Experiencing suicidal crisis ^05 17 
4. Attempted suicide 
X- = 7.05, p<0.009 
f) Rehospitalizatton 
0. Not required 1 44 35 
1 Required unrelated to the 
current illness 
2. Required due to side effects 
3. Required due to l„06 15 
additional stress 
4. Required due to relapse 
X- = 3 84. p<0.05 
g) Exacerbation 
0 No exacerbation ) 
1 -fc/lrtd behavioural exacerbation / 43 
2 Moderate exacerbation 
3. Severe exacerbation 
wrthouiadrr.ssion ^07 06 
4 Severe exacerbation 
with admission 
X
? = 0 068, NS. 
.} 
J 
r 
} 
} 
} 
y 
} 
haloperidoi group. At first sight it may appear as 
a bias of a clinician in favour of risperidone, 
especially in this kind of open trial, but it is Ihkely 
that due to overall improvement in other 
psychosocial areas, more number of patients 
received the rating of very much improved' on 
CGIS in risperidone group than in haloperidol 
group. This is evident from table-3, as 
significantly more number of patients could 
sustain education with satisfaction and were 
productive with or without support in the 
risperidone group than in haloperidol group. In 
addition, significantly more number of patients 
showed no suicidal intent' in risperidone group 
than in haloperidol group. 
The findings of the present study needs to 
be taken with caution in view of it being an open-
trial as well as descripency in the results on PANSS 
and Clinical Global Assessment. It is also difficult 
to rule out the possibility of better improvement on 
Clinical Global Assessment in risperidone group 
due to the possibility of lower rates of 
extrapyramidal reactions in risperidone group. 
In conclusion, from the findings of the 
present study it appears that though risperidone 
and haloperidol may be comparable as far as 
the improvement in signs and symptoms of 
schizophrenia is concerned, risperidone may 
have an edge over haloperidol as far as 
improvement in some of the psychosocial sreas 
and overall clinical improvement is concerned. 
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